Website Privacy Policy

As of July 8, 2025

Bambusa Therapeutics, Inc. and any of its subsidiaries (“Bambusa”, “we”, “us”, or “our”) recognize the importance of protecting your privacy. This Policy describes how Bambusa collects, uses, discloses or otherwise processes Personal Information in connection with this Website and any of our other websites, mobile applications, or online services that link to this Privacy Policy (collectively referred to as the “Sites”). If you do not agree with the terms of this Privacy Policy or the Terms of Use, or other terms and conditions on our Sites, then do not use our Sites.

Personal Information We Collect

Information you choose to provide to us. We may collect and store Personal Information that you provide voluntarily when using the Sites or otherwise share with us.

This includes:

  • Personal and Business Contact information, such as your first name and last name, postal address, email address, phone number, job title, and employer name;
  • Professional credentials, such as educational and work history, institutional affiliations and other information of the type that would be included on a resume or curriculum vitae;
  • Profile information, such as your username and password, industry, interests and preferences;
  • Feedback and correspondence, such as information you provide when you contact us with questions, report a problem with the Sites, receive customer support, respond to online surveys or otherwise correspond with us;
  • Transaction information, such as details about programs, events or other activities you register for through the Sites;
  • Usage information, such as information about how you use the Sites and interact with us; and
  • Marketing information, such as your preferences for receiving marketing communications.

Any communications relating to clinical trials should be made through the communication channels described in the applicable informed consent, patient information sheet or other instructions provided to clinical trial participants.

Information we collect automatically. We may automatically collect Personal Information about you when you visit any page on the Sites such as site usage information and information about your computer or mobile device. For example, we may record visitors’ host, domain name, pages visited, length of user session, browser type and/or IP address. We collect this information about you using cookies. Please refer to the section entitled Cookies and Similar Technologies below for more details. If you choose not to share your Personal Information with Bambusa, we may not be able to provide the activities or services listed in this Privacy Policy.

How We Use Your Personal Information

We may use your Personal Information for the following purposes:

  • To operate our Sites. We may use your Personal Information to:
    • Operate, maintain, administer and improve our Sites;
    • Process and manage registrations you make through our Sites;
    • Provide information about our research and development;
    • Communicate with you regarding our programs, events, or activities for which you may have registered, including by sending you technical notices, updates, security alerts, and support and administrative messages;
    • Understand your needs and interests, and personalize your experience with our Sites;
    • Provide support and maintenance for our Sites;
    • Respond to your service-related requests, questions and feedback.
  • To send you marketing and promotional communications. We may send you Bambusa-related marketing communications, as permitted by applicable law. You will have the ability to opt out of our marketing and promotional communications as described in the Opt-Out of Marketing section below.
  • To comply with law. We use your Personal Information as we believe necessary or appropriate to comply with applicable laws, lawful requests and legal processes, such as to respond to requests from government authorities.
  • With your consent. We may use or share your Personal Information with your consent, such as when you consent to let us post your testimonials or endorsements on our Sites, you instruct us to take a specific action with respect to your Personal Information, or you opt into third party marketing communications.
  • To create anonymous, aggregated or de-identified data. We may create anonymous, aggregated or de-identified data from your Personal Information. We may use this data and share it with third parties for our lawful business purposes, including to analyze and improve the Sites and our business.
  • For compliance, fraud prevention and safety. We may use your Personal Information as we believe necessary or appropriate to (a) enforce the terms and conditions that govern use of our Sites; (b) protect our rights, privacy, safety or property; and (c) protect, investigate and deter against fraudulent, harmful, unauthorized, unethical or illegal activity.

How We Disclose Your Personal Information

We may disclose your Personal Information to certain third parties in the following circumstances:

  • Affiliates. We may disclose your Personal Information to our subsidiaries and corporate affiliates for purposes consistent with the Privacy Policy.
  • Service Providers. We may share your Personal Information with third parties that provide services on our behalf (such as hosting, analytics, email delivery, marketing, and database management services). These third parties use Personal Information as directed by us and in a manner consistent with this Privacy Policy.
  • Professional advisors. We may also disclose Personal Information collected on the Sites to professional advisors, such as lawyers, auditors, bankers, and insurers, where necessary in the course of the professional services that they render to us.
  • Business transfers. We may also disclose your Personal Information to acquirers and other relevant participants in business transactions (or negotiations of or due diligence for such transactions) involving a corporate divestiture, merger, consolidation, acquisition, reorganization, sale or other disposition of all or any portion of the business or assets of, or equity interests in, Bambusa (including, in connection with a bankruptcy or similar proceedings), in which case we will honor this Privacy Policy and applicable law and make reasonable efforts to require the recipient to do so, too.
  • Compliance with Laws and Law Enforcement; Protection and Safety. We may also disclose Personal Information collected on the Sites, in accordance with applicable law, to assert or defend our rights and property, to prevent harm to others, to collect a debt, or in response to legal processes such as subpoenas. We may also provide (or reserve the right to provide) Personal Information to credit reporting agencies and to cooperate with law enforcement authorities and other governmental authorities consistent with applicable laws.

Your Rights

In this section, we describe the rights and choices available to all users (for residents in the EEA, UK, or Switzerland, please also see below).

Opt-out of marketing communications. You may opt-out of marketing-related emails by following the opt-out or unsubscribe instructions at the bottom of each such email, or by contacting us. Please note that if you choose to opt-out of marketing-related emails, you may continue to receive service-related and other non-marketing emails.

Do Not Track. Although our Sites currently do not have a mechanism to recognize the various web browser Do Not Track signals, we do offer you choices to manage your preferences as described in the sections above. To learn more about browser tracking signals and Do Not Track please visit: http://www.allaboutdnt.org.

Links To Third Party Sites

This Site may contain links to other third-party websites. Bambusa does not control the privacy policies or practices of these third-party websites. You should review those policies before providing any information. Bambusa is not responsible for the content or practices of any linked third-party websites, and we provide these links solely for the convenience and information of our visitors.

Security

Bambusa uses reasonable administrative, physical, and technical safeguards designed to protect the Personal Information we collect. However, security risk is inherent in all internet and information technologies, and we cannot guarantee complete security of your Personal Information. Any email or other communication purporting to be from one of our Sites asking you to provide sensitive information (including medical information) via email, should be treated as unauthorized and suspicious and should be reported to us immediately by emailing at privacy@bambusatx.com.

International Data Transfer

We are headquartered in the United States and we may use service providers that operate in other countries. Your Personal Information may be transferred to the United States or other locations where privacy laws may not be as protective as those in your state, province, or country. We will process and transfer your Personal Information in accordance with applicable law and this Privacy Policy regardless of where your Personal Information is stored or accessed. Our third-party service providers are contractually bound to treat Personal Information in a manner that is consistent with this Policy and applicable data protection laws. Residents in the European Economic Area (“EEA”), UK, or Switzerland will be provided with a copy of the safeguards in use upon their request via email to privacy@bambusatx.com

Children

These Sites are not directed at children and we do not knowingly collect Personal Information from children under the age of 16. If we learn that we have received Personal Information from a child under the age of 16, we will immediately delete it from our databases, systems and applications. If you learn that your child has provided us with Personal Information without your consent, you may contact us at privacy@bambusatx.com.

Residents of the European Economic Area, the United Kingdom or Switzerland

If you reside in the EEA, UK, or Switzerland, we are required to inform you of the legal bases of our processing of your Personal Information on our Sites, which include (1) to provide services, (2) for operation of the Sites, (3) to communicate with you, (4) for compliance, fraud prevention and safety purposes, (5) to create anonymous analytics, (6) to comply with law, and (7) with your consent. 

Retention of Data

We will only retain your Personal Information collected as described in this Policy for as long as necessary to fulfil the purposes for which it was collected (or for any subsequent purpose that is compatible with the original purpose). This does not affect your right to request that we delete your Personal Information before the end of its retention period. In some circumstances we may anonymize your Personal Information (so that it can no longer be associated with you) in which case we may use this information indefinitely without further notice to you.

Rights Regarding Your Personal Information

If you reside in the EEA, UK, or Switzerland, you may request that we take the following actions in relation to your Personal Information:

  • Access. Provide you with information about our processing of your Personal Information and give you access to your Personal Information.
  • Rectify. Update or correct inaccuracies in your Personal Information.
  • Delete. Delete your Personal Information, so long as its processing is no longer necessary or obligatory for the compliance with a legal obligation of Bambusa, or the defense of a lawful interest.
  • Transfer. Transfer a structured, commonly used and machine-readable copy of your Personal Information to you or a third party of your choice.
  • Restrict. Restrict the processing of your Personal Information.
  • Object. Object to our legitimate interests as the basis of our processing of your Personal Information.
  • Withdraw consent. Where our processing of your Personal Information is based on your consent, you have the right to withdraw it at any time, without this affecting the lawfulness of processing that took place prior to such withdrawal.

To submit a request, residents of the EEA, UK or Switzerland can write to us at our postal address provided below.

We will request specific information from you to help us confirm your identity and process your request. Applicable law may require or permit us to decline your request. If we decline your request, we will tell you why, subject to legal restrictions.

If you reside in the EEA, UK or Switzerland and would like to submit a complaint about our use of your Personal Information or response to your requests regarding your Personal Information, you may contact us or submit a complaint to the data protection regulatory authority in your country. All other inquiries regarding your Personal Information can be directed to privacy@bambusatx.com.

Cookies and Similar Technologies

How We Use Cookies

We may collect information using “cookies” and similar technologies. Cookies are alphanumeric identifiers that are transferred to your computer’s hard drive through your web browser to help us identify you when you come to our Sites. Our Sites use cookies to distinguish you from other users of our Sites. This helps us to provide you with a better experience when you use our Sites and allows us to improve our Sites. By virtue of their operation, cookies fall under the following categories:

  • Strictly Necessary Cookies: These cookies are required for the operation of our Sites. These cookies cannot be switched off. You can set your browser to block these cookies, but as a result, some parts of our Sites will not work as designed.
  • Functionality Cookies: These cookies allow our Sites to remember choices you make when you use our Sites. The purpose of these cookies is to provide you with a more personal experience and to avoid you from having to re-select your preferences every time you visit our Sites.

We may also use pixel tags (which are also known as web beacons and clear GIFs) on our Sites to track the actions of users on our Sites. Unlike cookies, which are stored on the hard drive of your computer or mobile device by a Sites, pixel tags are embedded invisibly on webpages. Pixel tags measure the success of our marketing campaigns and compile statistics about usage of the Sites, so that we can manage our content more effectively.

Information on Google Analytics

We may use third parties, such as Google Analytics to analyze traffic to our Sites. Google Analytics does not create individual profiles for visitors and only collects aggregate data. To disable Google Analytics, download the browser add-on for the deactivation of Google Analytics provided by Google at https://tools.google.com/dlpage/gaoptout. For more information on the use of Personal Information by Google Inc. please visit the Google privacy policy.

Disabling Cookies

If you do not accept our cookies, you may experience some inconvenience in your use of our Sites. For example, we may not be able to recognize your computer or mobile device and you may need to log in every time you visit our Sites.

Your choices for managing use of cookies include:

  • Blocking cookies in your browser. Most browsers let you remove or reject cookies. To do this, follow the instructions in your browser settings. Many browsers accept cookies by default until you change your settings. For more information about cookies, including how to see what cookies have been set on your device and how to manage and delete them, visit https://allaboutcookies.org/
  • Blocking advertising ID use in your mobile settings. Your mobile device settings may provide functionality to limit use of the advertising ID associated with your mobile device for interest-based advertising purposes.
  • Advertising industry opt-out tools. You can also use these opt-out options to limit use of your information for interest-based advertising by participating companies: Digital advertising Alliance: http://optout.aboutads.info; Network Advertising Initiative: http://optout.networkadvertising.org/

Changes to this Privacy Policy

Bambusa reserves the right to change this Policy to respond to new laws, regulations, technology, or for other business reasons. Please check the Sites from time to time to review any such changes. If we make material changes to this Policy, we will notify you by updating the date of this Policy and posting it on the Sites or other appropriate means. Any modifications to this Policy will be effective upon our posting the modified version (or as otherwise indicated at the time of posting).

Governing Law and Jurisdiction

You agree that any claim, action or proceeding arising out of this Policy, or your use of the Sites, shall be governed by and construed in accordance with the laws of the United States and the Commonwealth of Massachusetts, without regard to principles of conflict of laws. Any claim, action or proceeding related to this Policy will be resolved exclusively in the state or federal courts located in the Commonwealth of Massachusetts, and you consent to the jurisdiction of those courts.

Contact Information

If you have any questions or concerns about this Policy or would like to request this Privacy Policy in an alternative format due to a disability, you may contact us at privacy@bambusatx.com  or write to us at:

Bambusa Therapeutics, Inc.
22 Boston Wharf Rd, Floor 7
Boston MA 02210

Linkedin-in

Jon Lieber

Chief Financial Officer

Jonathan I. Lieber, MBA, is Chief Financial Officer of Bambusa Therapeutics. Jonathan brings more than 30 years of financial, strategic, and business experience across the life sciences industry.

Jonathan joined Bambusa from Rallybio Corporation, where he has served as Chief Financial Officer since 2023. Previously, he served as Chief Financial Officer of Applied Genetic Technologies Corporation and as a Managing Director at Danforth Advisors, where he provided strategic and operational financial leadership to life sciences companies. Earlier in his career, Jonathan served as Chief Financial Officer of Histogenics Corporation, Metamark Genetics, Repligen Corporation, Xcellerex, and Altus Pharmaceuticals. He began his career in healthcare investment banking at Salomon Brothers/Salomon Smith Barney and Cowen and Company/SG Cowen.

Jonathan currently serves on the boards of directors of Decoy Therapeutics, MindWalk Holdings, and Zola Therapeutics. He holds a B.S. in Business Administration and Finance from Boston University and an MBA in Finance from New York University’s Leonard N. Stern School of Business.

Todd James

Executive Vice President, Chief Financial Officer

Todd R. James serves as Chief Financial Officer of Bambusa Therapeutics, where he leads the company’s finance organization, capital markets strategy, and investor relations.

Prior to joining Bambusa, Mr. James founded TRJ BioAdvisors, where he advised biotechnology CEOs and Boards on capital markets strategy, investor relations, corporate communications, and special situations including mergers and acquisitions, shareholder activism defense, and clinical data disclosures.

Previously, Mr. James served as Senior Vice President of Corporate Affairs and Investor Relations at Viridian Therapeutics. Earlier, he held leadership roles of increasing responsibility at Acceleron Pharma, where he was a member of the Executive Committee and built the company’s investor relations, corporate communications, and broader external stakeholder engagement functions. During his tenure, he supported multiple public equity financings totaling more than $1 billion prior to the company’s $11.5 billion acquisition by Merck.

Earlier in his career, Mr. James served as a Senior Vice President at The Trout Group / Trout Capital and began his career at Thomson Financial providing capital markets intelligence to publicly traded biotechnology companies.

Mr. James has been recognized multiple times by Institutional Investor as a member of the All-America Executive Team for excellence in biotechnology investor relations. He holds a B.A. in Economics with a concentration in Finance from Moravian University.

Jen Salstrom

Vice President, Clinical Development

Bio here.

BBT002

Type 2 (T2) inflammatory diseases are characterized by skewed T2 immune responses driven by T2 cytokines including IL-4, IL-13, and IL-5. In specifics, IL-4 and IL-13, acting through IL-4Rα, promote Th2 polarization, IgE production, barrier dysfunction, mucus hypersecretion, and tissue remodeling, while IL-5 sustains eosinophil maturation, survival, and effector damage. These cytokines drive T2 inflammation across the airways, skin, and gut, contributing to diseases such as chronic obstructive pulmonary disease (COPD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), food allergy, chronic spontaneous urticaria (CSU), and eosinophilic esophagitis (EoE), and making them key therapeutic targets1. Dual targeting IL-4Rα and IL-5 offers advantages over single targeting of IL-4Rα or IL-5 or upstream alarmin proteins (e.g., TSLP, IL-33) by preventing escape (or “leakage”2) of the downstream T2 cytokines (IL-4, IL-13 and IL-5) and providing complete inhibition of the pathogenic inflammation.

BBT002 blocks the entire spectrum of Type 2 cytokines (IL-4, IL-13, and IL-5) while incorporating Fc mutations that eliminate unwanted effector functions and extend half-life for longer dosing intervals. The dual targeting design positions it to provide more comprehensive benefits over current single targeting therapies across T2 inflammatory diseases, particularly those with significant eosinophilic inflammation, while eliminating the risk of eosinophilia associated with anti-IL-4Rα monotherapy.

  1. Nature Reviews Immunology: Allergy and Immunology Study (2025) — https://www.nature.com/articles/s41423-025-01261-2
  2. Wiley Online Library: Allergy Journal Article (2023) — https://onlinelibrary.wiley.com/doi/full/10.1111/all.16537

BBT001

BBT001 is a bispecific IgG1 antibody for Type 2 inflammatory dermatological conditions. Using a 2+2 format, it simultaneously engages IL-4Rα and IL-31 to deliver faster and synergistic efficacy compared to existing treatments.

The drug incorporates Fc modifications that enhance FcRn affinity and extend half-life, enabling longer dosing intervals.

BBT001’s innovation addresses a critical treatment gap. While targeting IL4/13 tackles the fundamental Th2 inflammatory cascade, it does not effectively reduce IL-31 levels, providing only slow, moderate itch relief. This leaves patients trapped in the destructive “itch-scratch cycle” where continuous scratching compromises skin barrier function and perpetuates inflammation.

BBT001’s direct IL-31 targeting is designed to immediately affect sensory nerves, rapidly reducing itchiness while accelerating skin lesion improvement. This dual-pathway approach promises to break the itch-scratch cycle more effectively than single-target therapies, potentially transforming treatment for Type 2 inflammatory dermatological conditions.

Mike Malynn

Director, Finance

Mike Malynn is Director, Finance at Bambusa. Mike brings seven years of finance and operations experience scaling biotech companies and drives Bambusa’s financial strategy to support our mission of delivering transformative treatments. Prior to joining Bambusa, Mike led U.S. operations and supported portfolio companies from inception through seed stage as Finance Manager at Gordian Ventures. He was also the first finance employee at Silicon Therapeutics, where he built the finance function and helped drive the company’s acquisition by Roivant Sciences.

Based in Boston, Massachusetts, Mike holds a B.S.B.A in Business Economics from Suffolk University, graduating Summa Cum Laude.

Shaoyang Yeh, DPhil

Associate Director, CMC

Shaoyang Yeh, DPhil, is Associate Director of CMC at Bambusa Therapeutics. Shaoyang brings extensive process development and CMC experience from leadership roles at MabPlex USA (antibody drug conjugates), Emergent BioSolutions (Phase III vaccines), and BioLegend/Revvity (diagnostic antibodies and reagents). At MabPlex, he worked directly with clients on process design, technology transfer, and regulatory filings for novel biologic products.

Based in San Diego, Shaoyang holds bachelor’s degrees in Bioengineering and Biology from UC San Diego, a master’s in Biomedical Engineering from Cornell, and a DPhil in Engineering Science from Oxford, focusing on tissue engineering and bioprocessing.

Tracy Ji, MD

Director, Clinical Operations

Xiaoping (Tracy) Ji, MD is a Director, Clinical Operations at Bambusa. Leveraging over 19 years of clinical trial experience in her strategic leadership role, she previously served as Project Director at LabCorp, managing global Phase I-III trials across Australia, USA, and EU. Prior to LabCorp, Tracy worked with several global pharmaceutical companies including GSK, Novartis, Roche, and Eisai, gaining extensive knowledge in trial management from both sponsor and CRO perspectives.

 Based in Beijing, China, Tracy holds a Postgraduate Diploma in Public Health from the University of Auckland, New Zealand, complemented by a Bachelor of Clinical Medicine from Heilongjiang University of Chinese Medicine.

Wei Liang, PhD

Director, Development Sciences

Wei Liang, Ph.D., is the Director, Development Sciences at Bambusa and brings over 13 years of post-Ph.D. research and development experience across multiple disease areas to his role. Wei previously served as the Associate Director, R&D at Ansun Biopharma, where he led the cell therapy R&D programs and contributed to the development of a biologic drug candidate. Prior to that, he served as Associate Director I at BioDuro-Sundia, where he rebuilt and led its Oncology San Diego division.

Wei earned his B.S. from the University of Science and Technology of China and completed his Ph.D. at the City of Hope Comprehensive Cancer Center. He continued his research training with postdoctoral work at City of Hope and UC, San Diego.

Lisa Li, MD

Senior Director, Clinical Operations

Lisa Li is a Senior Director, Clinical Operations at Bambusa. Lisa brings extensive clinical operations expertise to her current role, with experience spanning a broad range of therapeutic areas, including infectious disease, dermatology, oncology, pain, rare disease, In addition to operational leadership, Lisa also contributed to corporate strategic initiatives, including supporting the sale of clinical assets during company restructuring at Vital Therapies.

Originally from Beijing, China, Lisa holds a medical degree and earned an MSc in Human Nutrition from the University of Glasgow. She is currently based in San Diego, California.

Jingjing Jiang, MD, PhD

Senior Director, Development Sciences

Dr. Jingjing Jiang is Senior Director of Development Sciences at Bambusa Therapeutics. With expertise in translational research and development sciences, she has a strong track record of building R&D teams, advancing therapeutic platforms, and bridging preclinical and clinical research. Jingjing has held roles at biotech companies of various sizes, including Poseida Therapeutics, contributing to innovative drug development across multiple therapeutic modalities.

Jingjing holds an M.D. from Zhejiang University and a Ph.D. in Biomedical Engineering from UC Irvine.

Melody Zhu, PhD

Vice President, Corporate Development and Strategy

Melody (Yun) Zhu, PhD, is the Vice President, Corporate Development & Strategy at Bambusa Therapeutics. Melody brings extensive cross-functional experience spanning R&D, business strategy, and external innovation across the pharmaceutical and biotech industries. Prior to joining Bambusa, Melody served as Director of External Innovations at BioNTech in Shanghai, where she led the search and evaluation of potential in-licensing opportunities, including assets from Duality and MediLink. Melody also held leadership roles at Sanofi driving portfolio development across Immunology & Inflammation and Oncology, contributing to programs including Dupixent and Itepekimab. She began her career in strategy consulting with Boston Consulting Group (BCG) and IQVIA.

Originally from China, Melody earned her Ph.D. in Biochemistry from The Chinese University of Hong Kong, and her B.S. in Biochemistry from Nanjing University.

Wei Lin, MD ScM

Vice President, Clinical Development

Wei Lin, MD, ScM, is Vice President of Clinical Development at Bambusa. Wei brings extensive experience in clinical development across the I&I therapeutic area. Prior to joining Bambusa, she served as Senior Director and Clinical Lead at Everest Medicines, where she was responsible for the global development of a BTK inhibitor in glomerular diseases. Previously, she was Director and Clinical Lead at Pfizer, overseeing rheumatology and inflammatory bowel disease (IBD) programs. There, she successfully led China’s Phase 3 development of tofacitinib for psoriatic arthritis and ankylosing spondylitis, resulting in NDA approvals. Her team also managed multiple clinical programs in systemic lupus erythematosus, ulcerative colitis, systemic juvenile idiopathic arthritis, and dermatomyositis in China.

Originally from Xiamen, China, Wei earned her MD from Peking University and holds a ScM in Epidemiology from Johns Hopkins University.

Wenbing Hu, PhD

Vice President, Head of CMC

Wenbing Hu, PhD, is Vice President and Head of CMC at Bambusa Therapeutics. Wenbing brings extensive expertise in biologics CMC development and manufacturing, previously serving as Senior Director of Pharmaceutical Development at Ansun Biopharma, where he led CMC activities for late-stage clinical trials. Prior to Ansun, Wenbing held leadership roles at Sorrento Therapeutics, overseeing analytical development, quality control, and formulation, and successfully advanced multiple antibody and mRNA projects through clinical phases. His deep experience spans from early-stage CMC development to global regulatory filings and GMP manufacturing operations.

Based in San Diego, California, Wenbing earned his PhD in Analytical Chemistry from the Institute of Chemistry, Chinese Academy of Sciences.

Crystal MacKay

Chief Operating Officer

Crystal MacKay is the Chief Operating Officer at Bambusa. Crystal brings extensive healthcare experience to her current role, having previously served as a Director of Healthcare Investment Banking at BTIG, where she was responsible for transaction execution in the Life Science & Diagnostic Tools and Medical Technology sectors. Crystal built operational expertise through leadership roles at innovative healthcare companies, including Oxford Immunotec, where she played a key role in strategic initiatives during the company’s transition, Strata Pathology Services, and Calloway Laboratories, where she served on the Board of Directors. 

Based in Boston, Massachusetts, Crystal holds a Bachelor of Arts in Business Communications from the University of Massachusetts and maintains securities licenses including SIE, Series 79, and Series 63.

Thang Ho, PhD

Co-Founder and Chief Development Officer

Thang Ho, Ph.D. is the Co-Founder and Chief Development Officer at Bambusa, where he leads an integrated team spanning preclinical research, translational medicine, toxicology, and clinical pharmacology while playing a critical role in shaping the company’s strategy across U.S. and global programs. Prior to Bambusa, Thang served as Director of Clinical Pharmacology and Pharmacometrics at BioNTech, leading clinical pharmacology strategies for innovative programs including cell and gene therapies and immuno-oncology agents. His career also includes scientific roles at Takeda, CytomX, and Vertex Pharmaceuticals.

Trained as a systems pharmacologist and engineer, Thang holds a Ph.D. in Chemical Engineering from the University of Pittsburgh, and earned his B.S. and M.S. in Chemical Engineering from the University of Arkansas. Originally from Da Nang, Viet Nam, Thang is based in Boston, Massachusetts.

Shanshan Xu, MD, PhD

Founder and Chief Executive Officer

Shanshan Xu, MD, PhD, is the Founder and Chief Executive Officer of Bambusa. Shanshan founded Bambusa with a belief that the I&I field is long overdue for innovative approaches and transformative cutting-edge solutions.

Prior to founding Bambusa, Shanshan served as Head of Global External Innovations at BioNTech, where she and her team sourced and executed 13 strategic partnerships and acquisitions to expand BNT’s pipeline. Her most notable accomplishment was identifying and acquiring Biotheus, which brought BNT327 (now partnered with BMS in a deal valued up to $11.1B). In addition, she identified the I&I molecules within Biotheus that ultimately became the foundation of Bambusa. Her portfolio also included the Duality, MediLink and OncoC4 partnerships, Tier 1 oncology programs. Before joining BioNTech in 2020, Shanshan worked on Wall Street as a Research Analyst.

Originally from Harbin, China, Shanshan spent almost half of her life in Mainland China, where she received her medical degree. She also holds a Ph.D. from UC-Irvine and an MBA from MIT.